G protein-coupled receptor 50Genealiases: H9 · Mel1c
Q-omics provides the consensus-scored GPR50 profile across patient tissues and cancer cell-line models. GPR50 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, GPR50 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, GPR50 RNA expression shows 9,113 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight STAD, HNSC, and TGCT as cancer lineages where GPR50 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR50 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR50 survival associations across molecular data types. GPR50 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR50 RNA expression–survival associations across cancer types. High GPR50 expression shows unfavorable associations in STAD, THCA, KIRC, LAML and READ, but favorable associations in SKCM. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for GPR50 RNA expression.
This table summarizes GPR50 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GPR50. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR50 shows lower tumor expression in BRCA, KIRC, KICH and KIRP and higher tumor expression in HNSC and LUSC. The HNSC box plot shows higher GPR50 RNA expression in tumor versus normal tissue (log2 FC = +1.607, t-test p < 0.001).
This table shows molecular features associated with GPR50 in patient tissues and cancer cell lines. In patient samples, GPR50 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR50 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
